Recent extremely meaningful positive changes in investment behavior have benefitted Sarepta Therapeutics Inc (NASDAQ: SRPT): positive upside/downside volume developed, its shorter term price trend turned up, and the stock rose on very heavy volume.
Recent minor positive changes in fundamentals have benefitted Sarepta Therapeutics Inc (NASDAQ: SRPT). Positive developments: significant quarterly sales acceleration occurred, and the consensus estimate for December, 2024 increased significantly. Negative development: the consensus estimate for December, 2025 decreased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
SRPT is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Sarepta Therapeutics has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Sarepta Therapeutics has a good Appreciation Score of 71 and a very high Power Rating of 89, resulting in the Highest Value Trend Rating.
Recent Price Action
Sarepta Therapeutics Inc (NASDAQ: SRPT) stock closed at $163.85 on 6/24/24 after an increase of 1.9%. Moreover, trading volume in this advance was exceptionally high at 220% of normal. The stock has risen 31.1% during the last week and has been exceptionally strong relative to the market over the last nine months.
Be the first to comment